NEWS
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
▪️55% of BriaCell patients1 remained alive one year since enrollment in BriaCell's Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patients
▪️Multiple outperforming patients with overall survival of over 2 years
▪️Survival benefit observed even in heavily pre-treated patients who failed treatment with checkpoint inhibitors (CPIs) and/or antibody-drug conjugates (ADCs)
▪️Final median overall survival calculation for the Phase 2 study is pending, as many patients remain alive
▪️No Bria-IMT™ related discontinuations reported to date
▪️Multiple outperforming patients with overall survival of over 2 years
▪️Survival benefit observed even in heavily pre-treated patients who failed treatment with checkpoint inhibitors (CPIs) and/or antibody-drug conjugates (ADCs)
▪️Final median overall survival calculation for the Phase 2 study is pending, as many patients remain alive
▪️No Bria-IMT™ related discontinuations reported to date
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2568Followers
107Following
28KVisitors
Follow
HannChau : no.volumes strange